Brain phosphoproteomics in aging without AD

(Phospho)proteomic studies in the human aging brain are based on the comparison between controls of bain aging usually affected by early stages of neurofibrillary tangle (NFT) pathology and subjects with moderate or advanced Alzheimer’s disease (AD).
(Phospho)proteomics using conventional label‐free‐ and SWATH‐MS (Sequential window acquisition of all theoretical fragment ion spectra mass spectrometry) has been assessed in the frontal cortex (FC) of individuals without NFTs and SPs, and comorbidities classified by age (years) in four groups; group 1 (young, 30-44); group 2 (middle-aged: MA, 45-52); group 3 (early-elderly, 64-70); and group 4 (late-elderly, 75-85).